Want to see CH:CURN full AI Analyst Report?
CURN Stock Chart & Stats
CHF20.30
CHF0.30(1.50%)
―
--
Day’s Range― - ―
52-Week RangeCHF10.90 - CHF27.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.42K
Market Cap
CHF105.99M
Enterprise ValueCHF119.29M
Total Cash (Recent Filing)CHF1.87M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta-1.27
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding5,301,199
10 Day Avg. Volume1,205
30 Day Avg. Volume1,417
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)1.30
Price to Sales (P/S)5.54
P/FCF Ratio-23.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.79
Revenue Forecast (FY)CHF99.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~57% top-line rebound signals durable commercial traction or successful portfolio recovery. Sustained revenue growth improves the ability to leverage fixed costs, supports scale of R&D/commercial investment, and creates a clearer path toward covering operating expenses over the next several quarters.
Gross Margin ImprovementImproving gross margins indicate better product mix, pricing power, or manufacturing efficiency. If sustained alongside revenue growth, this structural margin expansion can materially lift EBITDA conversion and reduce the absolute cash burn rate, aiding the transition toward sustainable profitability.
Debt-Free Balance SheetA debt-free, well-capitalized balance sheet provides financial flexibility to fund near-term operations, pursue partnerships or acquisitions, and withstand execution delays without immediate refinancing pressure. This reduces solvency risk and supports strategic optionality over the medium term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow show the business still burns cash despite better revenue. Continued cash outflows create funding and runway risk, potentially forcing dilutive financing or scaled-back investment in R&D/commercialization, which raises execution risk over months ahead.
Ongoing Net LossesProfitability remains elusive despite improvement; operating losses mean the company has not reached self-sufficiency. Without consistent positive earnings, management must rely on external capital or cost cuts, which can delay product rollouts and impair long-term return generation for shareholders.
Negative Return On EquityA negative ROE indicates the sizable equity base is not producing returns, reflecting inefficient capital use or early-stage commercialization. Continued negative returns increase the likelihood of future equity raises or dilution if management needs cash to scale operations or fund development programs.
Curatis Holding AG News
CURN FAQ
What was Curatis Holding AG’s price range in the past 12 months?
Curatis Holding AG lowest stock price was CHF10.90 and its highest was CHF27.90 in the past 12 months.
What is Curatis Holding AG’s market cap?
Curatis Holding AG’s market cap is CHF105.99M.
When is Curatis Holding AG’s upcoming earnings report date?
Curatis Holding AG’s upcoming earnings report date is Sep 21, 2026 which is in 41 days.
How were Curatis Holding AG’s earnings last quarter?
Curatis Holding AG released its earnings results on Mar 24, 2026. The company reported -CHF0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.049.
Is Curatis Holding AG overvalued?
According to Wall Street analysts Curatis Holding AG’s price is currently Undervalued.
Does Curatis Holding AG pay dividends?
Curatis Holding AG does not currently pay dividends.
What is Curatis Holding AG’s EPS estimate?
Curatis Holding AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curatis Holding AG have?
Curatis Holding AG has 5,301,199 shares outstanding.
What happened to Curatis Holding AG’s price movement after its last earnings report?
Curatis Holding AG reported an EPS of -CHF0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Curatis Holding AG?
Currently, no hedge funds are holding shares in CH:CURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.